Literature DB >> 12187170

Measuring complications of cancer treatment using the SEER-Medicare data.

Arnold L Potosky1, Joan L Warren, Elyn R Riedel, Carrie N Klabunde, Craig C Earle, Colin B Begg.   

Abstract

BACKGROUND: The linkage of SEER registry data with Medicare claims allows the longitudinal tracking of health care and outcomes for patients after a cancer diagnosis. One category of outcomes amenable to research using Medicare claims is complications of cancer treatments: the unintentional, adverse side effects or sequelae of interventions used to treat or palliate cancer patients. RESEARCH
DESIGN: The authors review some of the methods and limitations of using Medicare claims to identify both acute and chronic complications of cancer treatments, and present an original analysis comparing survey-based and claims-based complications following radical prostatectomy for prostate cancer to illustrate some of the potential limitations inherent in using claims for this purpose.
RESULTS: Utility of the Medicare claims for identifying postdischarge complications varies by the patient type, the initial treatment used, and any subsequent treatment of complications. For patients undergoing surgical interventions, Medicare claims can be used to identify most acute inpatient complications. However, claims data cannot be used as effectively in the long-term to capture chronic complications, particularly when the complication does not consistently prompt an intervention.
CONCLUSION: Researchers who use the SEER-Medicare-linked database to assess long-term complications of cancer treatments should exercise caution when designing and interpreting studies. Ideally, for studies of most chronic complications of cancer care, validation studies similar to the one performed here would provide valuable additional evidence to assess the credibility of conclusions based on claims data.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12187170     DOI: 10.1097/00005650-200208001-00009

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  50 in total

1.  Treatment-related toxicities in older adults with head and neck cancer: A population-based analysis.

Authors:  Caitriona B O'Neill; Shrujal S Baxi; Coral L Atoria; James P O'Neill; Martin C Henman; Eric J Sherman; Nancy Y Lee; David G Pfister; Elena B Elkin
Journal:  Cancer       Date:  2015-02-27       Impact factor: 6.860

2.  Trends in the treatment of acute myeloid leukaemia in the elderly.

Authors:  Kathleen Lang; Craig C Earle; Talia Foster; Deirdre Dixon; Renilt Van Gool; Joseph Menzin
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer.

Authors:  Justin E Bekelman; Nandita Mitra; Jason Efstathiou; Kaijun Liao; Robert Sunderland; Deborah N Yeboa; Katrina Armstrong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-16       Impact factor: 7.038

4.  Development of a patient registry to evaluate hospital admissions related to chemotherapy toxicity in a community cancer center.

Authors:  Monika K Krzyzanowska; Jean Treacy; Betty Maloney; Antoinette Lavino; Joseph O Jacobson
Journal:  J Oncol Pract       Date:  2005-05       Impact factor: 3.840

5.  External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews.

Authors:  Xianglin L Du; Charles R Key; Lois Dickie; Ronald Darling; Jane M Geraci; Dong Zhang
Journal:  Med Care       Date:  2006-02       Impact factor: 2.983

Review 6.  Cancer survivorship research in Europe and the United States: where have we been, where are we going, and what can we learn from each other?

Authors:  Julia H Rowland; Erin E Kent; Laura P Forsythe; Jon Håvard Loge; Lars Hjorth; Adam Glaser; Vittorio Mattioli; Sophie D Fosså
Journal:  Cancer       Date:  2013-06-01       Impact factor: 6.860

7.  Variation in quality of care among older men with localized prostate cancer.

Authors:  Ravishankar Jayadevappa; Sumedha Chhatre; Jerry C Johnson; S Bruce Malkowicz
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

8.  Five-year downstream outcomes following prostate-specific antigen screening in older men.

Authors:  Louise C Walter; Kathy Z Fung; Katharine A Kirby; Ying Shi; Roxanne Espaldon; Sarah O'Brien; Stephen J Freedland; Adam A Powell; Richard M Hoffman
Journal:  JAMA Intern Med       Date:  2013-05-27       Impact factor: 21.873

9.  Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.

Authors:  Dawn L Hershman; Donna L Buono; Jennifer Malin; Russell McBride; Wei Yann Tsai; Alfred I Neugut
Journal:  J Natl Cancer Inst       Date:  2009-11-10       Impact factor: 13.506

10.  Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity.

Authors:  James B Yu; Pamela R Soulos; Jeph Herrin; Laura D Cramer; Arnold L Potosky; Kenneth B Roberts; Cary P Gross
Journal:  J Natl Cancer Inst       Date:  2012-12-14       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.